Evommune EVMN Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.65M+3.5% | $1.49M-11.0% | $1.69M+21.4% | $1.83M— | $1.59M— | ||
| $684.39K-5.4% | $823.77K+19.3% | $715.82K+13.2% | $864.44K— | $723.49K— | ||
| $961.13K+10.9% | $670.76K-32.2% | $978.35K+28.1% | $968.1K— | $866.76K— | ||
| 58.4%+3.9pp | 44.9%-14.0pp | 57.7%+3.0pp | 52.8%— | 54.5%— | ||
| $263.71K+47.6% | $169.87K+39.7% | $118.88K-24.0% | $165.04K— | $178.63K— | ||
| $1.38M+91.6% | $1.63M+62.8% | $937.76K+13.5% | $958.49K— | $720.23K— | ||
| $1.64M+82.9% | $1.8M+60.3% | $1.06M+7.5% | $1.12M— | $898.86K— | ||
| -$682.81K-2,027% | -$1.13M-734% | -$78.29K+64.2% | -$155.44K— | -$32.1K— | ||
| -41.5%-39.5pp | -75.8%-67.7pp | -4.6%+11.1pp | -8.5%— | -2%— | ||
| $25.8K-72.9% | $80.98K-43.1% | $155.31K+123% | $71.01K— | $95.09K— | ||
| -$6.99M-5,414% | $852.32K+407% | $259K+190% | —— | -$126.78K— | ||
| -424.8%-417pp | 57%+73.6pp | 15.3%+35.9pp | —— | -8%— | ||
| -$0.36-1,700% | $0.02+150% | $0.04+200% | —— | -$0.02— | ||
| -$678.22K-2,521% | -$1.13M-782% | -$73.35K+65.1% | —— | -$25.88K— | ||
| -41.2%-39.6pp | -75.5%-67.9pp | -4.3%+10.7pp | —— | -1.6%— | ||
| -$682.81K-2,027% | -$1.13M-734% | -$78.29K+64.2% | -$155.44K— | -$32.1K— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Evommune 's revenue?
- Evommune (EVMN) generated $6.7M in revenue over the trailing twelve months.
- Is Evommune profitable?
- Evommune is not currently profitable: it reported a net loss of $6.0M over the trailing twelve months, a -90.1% net margin.
- What are Evommune 's profit margins?
- Gross margin is 53.7% and operating margin is -30.7%, with a -90.1% net margin.
- What is Evommune 's earnings per share?
- Evommune 's diluted EPS over the trailing twelve months is $-0.32.
- Where does Evommune 's income statement data come from?
- Every line is extracted from Evommune 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
